Create Free Account

By creating account you will get access to hot stocks & personalised emails

Anteris Technologies Ltd

Healthcare AU AVR

5.4AUD
0.88(19.47%)

Last update at 2025-04-10T06:10:00Z

Day Range

5.205.50
LowHigh

52 Week Range

5.6023.93
LowHigh

Fundamentals

  • Previous Close 4.52
  • Market Cap334.61M
  • Volume14518
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-92.29606M
  • Revenue TTM3.89M
  • Revenue Per Share TTM0.22
  • Gross Profit TTM 1.63M
  • Diluted EPS TTM-5.05

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -44.34016M -22.90703M -15.27453M -6.18138M -24.69868M
Minority interest - - - 0.36M 0.36M
Net income -45.25318M -25.77193M -17.51983M -30.75166M -24.21717M
Selling general administrative 22.45M 13.95M 11.76M 20.94M 23.52M
Selling and marketing expenses 1.18M 0.55M 0.59M 1.47M -
Gross profit 2.61M 6.15M 6.51M 8.30M 12.44M
Reconciled depreciation 1.74M 1.35M 1.21M 1.62M 1.41M
Ebit -43.42714M -21.56553M -14.90227M -1.10860M -21.57885M
Ebitda -41.68522M -20.21134M -13.68970M 0.51M -20.16807M
Depreciation and amortization 1.74M 1.35M 1.21M 1.62M 1.41M
Non operating income net other - - - - -
Operating income -43.42714M -21.56553M -14.90227M -1.10860M -23.26374M
Other operating expenses 51.98M 30.80M 25.99M 42.65M 48.86M
Interest expense 0.91M 1.34M 0.37M 0.29M 2.64M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.31M 0.09M 0.19M 0.07M 0.04M
Net interest income -0.76928M -1.42275M -0.18725M -0.22405M -2.59648M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.91M 2.86M 2.25M 24.57M -
Total revenue 4.59M 7.79M 9.24M 17.08M 25.60M
Total operating expenses 49.99M 29.16M 23.27M 33.88M 35.70M
Cost of revenue 1.98M 1.64M 2.72M 8.77M 13.16M
Total other income expense net -0.91302M -1.34150M -0.37226M -5.07278M -1.43494M
Discontinued operations - - - - -
Net income from continuing ops -44.34016M -22.90703M -15.27453M -6.18138M -24.69868M
Net income applicable to common shares -44.34016M -22.90703M -15.27453M -5.81967M -24.21717M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 130.39M 45.70M 23.48M 29.48M 12.65M
Intangible assets 0.31M - 0.90M 1.15M 1.42M
Earning assets - - - - -
Other current assets 5.33M 3.14M 1.40M 1.20M 1.46M
Total liab 29.11M 17.04M 10.26M 15.13M 10.24M
Total stockholder equity 101.40M 28.60M 13.22M 14.35M 2.41M
Deferred long term liab - - - - -
Other current liab 16.03M 8.26M 4.23M 4.56M 0.40M
Common stock 0.00646M 282.99M 211.83M 172.64M 138.74M
Capital stock 350.04M - 211.83M 172.64M 138.74M
Retained earnings -446.56009M -270.42431M -202.01977M -157.67961M -134.77258M
Other liab - - 2.07M 1.77M 1.58M
Good will - - - - 0.00000M
Other assets - 0.00000M - - 0.71M
Cash 113.84M 30.83M 13.81M 21.30M 4.35M
Cash and equivalents - - - - -
Total current liabilities 26.76M 13.83M 7.54M 12.94M 7.84M
Current deferred revenue 0.00000M - - - 3.73M
Net debt -111.58509M -28.49903M -12.39900M -15.57040M -0.57140M
Short term debt 1.21M 0.98M 0.76M 5.31M 2.95M
Short long term debt 0.00300M - - 4.68M 2.55M
Short long term debt total 2.25M 2.33M 1.41M 5.73M 3.78M
Other stockholder equity 565.55M - -1.50685M -0.61057M -1.56022M
Property plant equipment - - 4.52M 2.50M 2.43M
Total current assets 120.61M 35.89M 18.07M 25.84M 8.09M
Long term investments - - - - -
Net tangible assets - - 12.32M 13.20M 0.99M
Short term investments - - 0.09M 0.09M 0.11M
Net receivables 0.62M 1.27M 0.83M 2.59M 1.58M
Long term debt - - 1.38M 1.21M 0.94M
Inventory 0.83M 0.65M 0.52M 0.76M 0.69M
Accounts payable 9.51M 4.59M 2.55M 3.07M 0.75M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -17.59659M 16.04M 3.41M -0.61057M -1.56022M
Additional paid in capital - - - - -
Common stock total equity - - - - 138.74M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00000M 1.38M - - 0.71M
Deferred long term asset charges - - - - -
Non current assets total 9.77M 9.81M 5.41M 3.64M 4.56M
Capital lease obligations 1.39M - 1.41M 1.05M 1.23M
Long term debt total - - 2.03M 1.63M 1.77M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1.36029M -0.40000M 7.11M -7.53674M -0.40000M
Change to liabilities 0.53M 1.50M -0.90809M -2.25555M 1.33M
Total cashflows from investing activities -1.36029M -1.16221M 7.76M 20.57M -1.01122M
Net borrowings -2.06279M 1.15M 0.86M 0.71M -5.00000M
Total cash from financing activities 31.36M 36.91M 1.89M 0.00873M 27.15M
Change to operating activities 0.30M -0.06593M -0.02033M -0.35644M 0.16M
Net income -45.25318M -22.90703M -15.27453M -5.81967M -24.21717M
Change in cash -7.49454M 16.95M -4.61403M -3.06791M 3.78M
Begin period cash flow 21.30M 4.35M 8.97M 12.04M 8.25M
End period cash flow 13.81M 21.30M 4.35M 8.97M 12.04M
Total cash from operating activities -43.51126M -18.80961M -14.37316M -22.86730M -22.20531M
Issuance of capital stock 34.89M 36.85M 1.07M 0.00014M 35.41M
Depreciation 1.74M 1.35M 1.21M 1.62M 1.41M
Other cashflows from investing activities 1.05M -0.38955M 8.05M 20.64M -0.40000M
Dividends paid - 5.00M - - -
Change to inventory 0.23M -0.06428M 1.12M 2.03M -1.13824M
Change to account receivables -0.98395M -0.05193M 5.87M -5.20490M 0.53M
Sale purchase of stock -1.46771M -1.08997M 1.07M -0.64056M -3.06868M
Other cashflows from financing activities -0.71279M 8.94M 0.82M 0.65M 4.81M
Change to netincome 2.80M 0.41M -6.47100M -12.96405M -0.95449M
Capital expenditures 2.41M 0.77M 0.29M 0.07M 0.61M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.85M 1.60M 2.45M 0.05M 0.08M
Stock based compensation - - - - -
Other non cash items 43.51M 21.55M 14.06M 4.20M 22.81M
Free cash flow -45.92016M -19.58227M -14.66169M -22.93446M -22.81653M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AVR
Anteris Technologies Ltd		 0.88 19.47% 5.40 - - 76.27 2.18 23.79 -5.1986
COH
Cochlear Ltd		 6.98 2.79% 256.76 47.38 38.61 7.58 9.41 7.55 29.20
PNV
Polynovo Ltd		 0.10 10.36% 1.06 110.20 52.36 6.59 10.07 7.24 184.50
EBR
Ebr Systems Inc CDR		 0.28 21.21% 1.60 - - - 15.93 - -3.6785
IMR
Imricor Medical Systems Inc		 0.17 14.83% 1.35 - - 417.34 3.97 299.70 -2.6027

Reports Covered

Stock Research & News

View All

Profile

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

Anteris Technologies Ltd

Toowong Tower, Toowong, QLD, Australia, 4066

  • 61 7 3152 3200
  • Employees : 136

Key Executives

Name Title Year Born
Mr. Wayne G. Paterson CEO, MD & Exec. Director 1967
Mr. Matthew McDonnell Chief Financial Officer NA
Mr. David St. Denis Chief Operating Officer NA
Mr. Stephen Denaro Independent Non-Exec. Director & Company Sec. NA
Mr. Chris Olig Bus. Devel. and Portfolio Planning Director NA
Dr. Chris Meduri M.D., M.P.H. Chief Medical Officer & Member of Medical Advisory Board NA
Mr. Danny Zanardo Commercial Director of International NA
Prof. Ian Hector Frazer AC, FAA, FRS, M.D. Exec. NA
Mr. Wayne G. Paterson CEO, MD & Executive Director 1967
Mr. Stephen Denaro Independent Non-Executive Director & Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

Market Research
ISO Certified pcidss

Kalkine Solutions Private Limited, an authorized representative of Kalkine Pty Ltd, holds the ISO 27001:2022 certification (Certificate No. IC-IS-2404072) and the PCI-DSS Version 4.0 Level 1 certification (Certificate No. CSNL1PCI8067).

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2025 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.